Wolverine

Wolverine is a community name for a two-peptide product sold in one vial, not a single compound or an approved medicine. It contains BPC-157 and TB-500, which are the two ingredients that give it its research identity. Community practice discusses the pair mainly for tendon, ligament, and soft-tissue recovery. Because the name is a vendor label, the exact amounts can vary between sellers; the label records a composition, but it does not independently verify it. The wider peptide market has documented products sold without verification of identity or purity ¹.

BPC-157

BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein fraction of human gastric juice ³. It is studied in animals and cells for soft-tissue repair, gastrointestinal protection, and nitric-oxide-signaling effects, with human evidence comprising three uncontrolled pilot studies and a completed Phase II ulcerative colitis trial with reported no side effects; no published randomized controlled trials exist ⁵. The strongest evidence is preclinical: rat models of tendon, ligament, and muscle injury show improved healing, but no randomized controlled human trial exists ⁷.

TB-500

TB-500 is the synthetic N-terminal acetylated 17-23 fragment of thymosin beta-4, containing the actin-binding region ⁹. Direct research on TB-500 is sparse: the clearest efficacy datum is one rat Achilles tendon study in which it improved maximum load to failure ¹⁰. Most claims for tissue repair are extrapolated from full-length thymosin beta-4, which has human trial data in cardiac and ocular settings but not musculoskeletal injury ¹¹. Its human musculoskeletal evidence is absent ¹³.

Mechanistically, BPC-157 and TB-500 overlap in angiogenesis, cell migration, and inflammatory-resolution signaling (BPC-157: ⁷; TB-500/thymosin beta-4: ¹⁵), so the combination may be more redundant than additive ¹⁰. The only controlled combination study found that adding BPC-157 to TB-500 in a rat Achilles tendon model produced no additive benefit over TB-500 alone, and BPC-157 alone did not reach significance on all endpoints ¹⁰. The interaction evidence therefore points to shared downstream pathways rather than distinct, stackable effects. No published study has tested this exact combination as sold; the component-level animal study is the closest available evidence.

The community use for Wolverine concentrates on tendon, ligament, and soft-tissue recovery. The evidence is component-level, and human data are much thinner than animal data.

The broadest single-agent human data remain the three BPC-157 pilots, which were uncontrolled and reported no adverse events, but were not designed to establish efficacy ¹⁶.

Wolverine is sold as a fixed-ratio product: the two peptides come in one vial, so a single draw delivers both together and neither peptide can be adjusted on its own. No standardized mg-per-vial amount is documented; vendors sell the same name at different ratios, so the label on the vial is what determines the stated amounts, which are not independently verified. Choosing a draw for one component therefore fixes the amount of the other, even though the exact proportion is not standardized. A vial total is not a dose, and this page does not compare vial amounts with study doses. An interactive calculator on the page handles the volume and concentration math.

Lyophilized BPC-157 and TB-500 are handled in research and community protocols by reconstituting with bacteriostatic water and mixing gently rather than shaking. The reconstituted vials are kept refrigerated, protected from light, and discarded within the shorter of the two components' suggested windows; community practice commonly uses 14 days. Analytical stability data show both peptides degrade in liquid serum within about one week at 4°C or 22°C, and both remain stable at -20°C for at least two months ²⁴. BPC-157 resists degradation in gastric juice for more than 24 hours, but that does not establish oral bioavailability for the blend ⁵. The interactive calculator in this section handles the specific diluent volumes and concentrations, so no per-dose math is repeated here.

BPC-157

No randomized human safety trial exists. The three uncontrolled pilots reported no adverse events among 26 subjects ⁷. Theoretical risks include NO-mediated vasorelaxation and hypotension ²⁵, and an unresolved debate about pro-angiogenic versus anti-tumor effects ¹. The largest real-world concerns are contaminated or mislabeled unregulated product ¹.

TB-500

No human safety data exist for the fragment itself ¹³. Parent thymosin beta-4 had no peptide-attributable safety signals in one 96-patient myocardial infarction RCT ¹², but its pro-migratory and pro-angiogenic biology creates a theoretical cancer/pathological-vessel concern ⁶. Animal data also implicate thymosin beta-4 in platelet and coagulation pathways ²⁹.

Combined unknowns

When the two are put in one vial, the unknowns combine. The only controlled combination exposure is the rat Achilles study, which reported no treatment-related deaths or adverse events flagged, but it was not a human safety study ¹⁰. People with active cancer, bleeding disorders, or competitive-athlete status are the groups most often flagged by the evidence ¹.

A blend inherits the most restrictive status among its components. Because both components are unapproved and fall under WADA's S0 category for non-approved substances, Wolverine has the same standing: no approved medical use, and prohibited in competitive sport ⁶.